Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial

NCT02678975 is registered in ClinicalTrials.gov with Sahlgrenska University Hospital as lead sponsor.

NCT NCT02678975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02678975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial
Lead sponsor
Sahlgrenska University Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2017
Completion date
January 15, 2021
Enrollment
88 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioma